Auxenion combines established scientific disciplines: chemistry, phenotypic biology, proteomics, and bioinformatics, in an integrated way to identify active compounds and investigate their mechanisms of action.
Our differentiation lies not in inventing new methods, but in how we use them together. This integration connects molecular structure to biological activity and therapeutic potential within one unified process.
We use a target-agnostic drug discovery process. Instead of starting with a predefined biological target, compounds are investigated based on their effects in relevant biological systems, letting biology guide the path to therapeutic relevance. This approach reduces risk, fosters innovation and improves the likelihood of translating findings into meaningful clinical outcomes.
Chemistry, biology, proteomics, and bioinformatics work in tandem to characterize compounds, study biological effects, and investigate their mechanisms. This integrated approach connects molecular structure to biological activity and therapeutic potential, enabling rapid deconvolution of complex phenotypic readouts into actionable mechanistic insights.
Scientific findings are converted into pharmaceutical assets with potential commercial value and relevance to significant unmet medical needs. Our intellectual property strategy is designed to protect both the underlying chemical matter and the potential uses of our patented library, creating a pipeline of differentiated programs with clear development paths.
